Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer

Eddy S. Yang, Carol A. Maiorino, Bernard A. Roos, Selena R. Knight, Kerry L Burnstein

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

1,25-(OH)2 vitamin D3 (1,25-(OH)2 D), the active metabolite of vitamin D, exerts antiproliferative effects on a variety of tumor cells including prostate. This inhibition requires vitamin D receptors (VDRs) as well as downstream effects on the G1 to S phase checkpoint of the cell cycle. Recent data raise the possibility that androgen plays a role in the antiproliferative effects of 1,25-(OH)2 D in prostate cancer cells; however, this hypothesis has been difficult to test rigorously as the majority of prostate cancer cell lines (unlike human prostate tumors) lack androgen receptors (ARs). We utilized two different models of androgen-independent prostate cancer that express functional ARs and VDRs to evaluate a possible role of androgen in 1,25-(OH)2 D mediated growth inhibition. We stably introduced the AR cDNA into the human prostate cancer cell line ALVA 31, which expresses functional VDR but is relatively resistant to growth inhibition by 1,25-(OH)2 D. Neither ALVA-AR nor the control cells, ALVA-NEO, exhibited substantial growth inhibition by 1,25-(OH)2 D in the presence or absence of androgen. This observation suggests that the basis for the resistance of ALVA 31 to 1,25-(OH)2 D-mediated growth inhibition is not the lack of AR. The second model was LNCaP-104R1, an AR-expressing androgen independent prostate cancer cell line derived from androgen dependent LNCaP. 1,25-(OH)2 D inhibited the growth of LNCaP-104R1 cells in the absence of androgen and this effect was not blocked by the antiandrogen Casodex. As was observed in the parental LNCaP cells, this effect was correlated with G1 phase cell cycle accumulation and upregulation of the cyclin dependent kinase inhibitor (CKI) p27, as well as increased association of p27 with cyclin dependent kinase 2. These findings suggest that the antiproliferative effects of 1,25-(OH)2 D do not require androgen-activated AR but do involve 1,25-(OH)2 D induction of CKIs required for G1 cell cycle checkpoint control.

Original languageEnglish
Pages (from-to)69-79
Number of pages11
JournalMolecular and Cellular Endocrinology
Volume186
Issue number1
StatePublished - Jan 15 2002

Fingerprint

Vitamin D
Androgen Receptors
Androgens
Prostatic Neoplasms
Cells
Cell Line
Growth
Calcitriol Receptors
G1 Phase Cell Cycle Checkpoints
Tumors
Prostate
Cyclin-Dependent Kinase 2
Cyclin-Dependent Kinase Inhibitor p27
Androgen Antagonists
Cholecalciferol
G1 Phase
Metabolites
Cell Cycle Checkpoints
Neoplasms
Cell Cycle

Keywords

  • Androgen independence
  • Androgen receptor
  • Cyclin dependent kinase inhibitor
  • p21
  • p27
  • Vitamin D receptor

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. / Yang, Eddy S.; Maiorino, Carol A.; Roos, Bernard A.; Knight, Selena R.; Burnstein, Kerry L.

In: Molecular and Cellular Endocrinology, Vol. 186, No. 1, 15.01.2002, p. 69-79.

Research output: Contribution to journalArticle

Yang, Eddy S. ; Maiorino, Carol A. ; Roos, Bernard A. ; Knight, Selena R. ; Burnstein, Kerry L. / Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. In: Molecular and Cellular Endocrinology. 2002 ; Vol. 186, No. 1. pp. 69-79.
@article{269ea7e1c9094241bb26c1c6e2145397,
title = "Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer",
abstract = "1,25-(OH)2 vitamin D3 (1,25-(OH)2 D), the active metabolite of vitamin D, exerts antiproliferative effects on a variety of tumor cells including prostate. This inhibition requires vitamin D receptors (VDRs) as well as downstream effects on the G1 to S phase checkpoint of the cell cycle. Recent data raise the possibility that androgen plays a role in the antiproliferative effects of 1,25-(OH)2 D in prostate cancer cells; however, this hypothesis has been difficult to test rigorously as the majority of prostate cancer cell lines (unlike human prostate tumors) lack androgen receptors (ARs). We utilized two different models of androgen-independent prostate cancer that express functional ARs and VDRs to evaluate a possible role of androgen in 1,25-(OH)2 D mediated growth inhibition. We stably introduced the AR cDNA into the human prostate cancer cell line ALVA 31, which expresses functional VDR but is relatively resistant to growth inhibition by 1,25-(OH)2 D. Neither ALVA-AR nor the control cells, ALVA-NEO, exhibited substantial growth inhibition by 1,25-(OH)2 D in the presence or absence of androgen. This observation suggests that the basis for the resistance of ALVA 31 to 1,25-(OH)2 D-mediated growth inhibition is not the lack of AR. The second model was LNCaP-104R1, an AR-expressing androgen independent prostate cancer cell line derived from androgen dependent LNCaP. 1,25-(OH)2 D inhibited the growth of LNCaP-104R1 cells in the absence of androgen and this effect was not blocked by the antiandrogen Casodex. As was observed in the parental LNCaP cells, this effect was correlated with G1 phase cell cycle accumulation and upregulation of the cyclin dependent kinase inhibitor (CKI) p27, as well as increased association of p27 with cyclin dependent kinase 2. These findings suggest that the antiproliferative effects of 1,25-(OH)2 D do not require androgen-activated AR but do involve 1,25-(OH)2 D induction of CKIs required for G1 cell cycle checkpoint control.",
keywords = "Androgen independence, Androgen receptor, Cyclin dependent kinase inhibitor, p21, p27, Vitamin D receptor",
author = "Yang, {Eddy S.} and Maiorino, {Carol A.} and Roos, {Bernard A.} and Knight, {Selena R.} and Burnstein, {Kerry L}",
year = "2002",
month = "1",
day = "15",
language = "English",
volume = "186",
pages = "69--79",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer

AU - Yang, Eddy S.

AU - Maiorino, Carol A.

AU - Roos, Bernard A.

AU - Knight, Selena R.

AU - Burnstein, Kerry L

PY - 2002/1/15

Y1 - 2002/1/15

N2 - 1,25-(OH)2 vitamin D3 (1,25-(OH)2 D), the active metabolite of vitamin D, exerts antiproliferative effects on a variety of tumor cells including prostate. This inhibition requires vitamin D receptors (VDRs) as well as downstream effects on the G1 to S phase checkpoint of the cell cycle. Recent data raise the possibility that androgen plays a role in the antiproliferative effects of 1,25-(OH)2 D in prostate cancer cells; however, this hypothesis has been difficult to test rigorously as the majority of prostate cancer cell lines (unlike human prostate tumors) lack androgen receptors (ARs). We utilized two different models of androgen-independent prostate cancer that express functional ARs and VDRs to evaluate a possible role of androgen in 1,25-(OH)2 D mediated growth inhibition. We stably introduced the AR cDNA into the human prostate cancer cell line ALVA 31, which expresses functional VDR but is relatively resistant to growth inhibition by 1,25-(OH)2 D. Neither ALVA-AR nor the control cells, ALVA-NEO, exhibited substantial growth inhibition by 1,25-(OH)2 D in the presence or absence of androgen. This observation suggests that the basis for the resistance of ALVA 31 to 1,25-(OH)2 D-mediated growth inhibition is not the lack of AR. The second model was LNCaP-104R1, an AR-expressing androgen independent prostate cancer cell line derived from androgen dependent LNCaP. 1,25-(OH)2 D inhibited the growth of LNCaP-104R1 cells in the absence of androgen and this effect was not blocked by the antiandrogen Casodex. As was observed in the parental LNCaP cells, this effect was correlated with G1 phase cell cycle accumulation and upregulation of the cyclin dependent kinase inhibitor (CKI) p27, as well as increased association of p27 with cyclin dependent kinase 2. These findings suggest that the antiproliferative effects of 1,25-(OH)2 D do not require androgen-activated AR but do involve 1,25-(OH)2 D induction of CKIs required for G1 cell cycle checkpoint control.

AB - 1,25-(OH)2 vitamin D3 (1,25-(OH)2 D), the active metabolite of vitamin D, exerts antiproliferative effects on a variety of tumor cells including prostate. This inhibition requires vitamin D receptors (VDRs) as well as downstream effects on the G1 to S phase checkpoint of the cell cycle. Recent data raise the possibility that androgen plays a role in the antiproliferative effects of 1,25-(OH)2 D in prostate cancer cells; however, this hypothesis has been difficult to test rigorously as the majority of prostate cancer cell lines (unlike human prostate tumors) lack androgen receptors (ARs). We utilized two different models of androgen-independent prostate cancer that express functional ARs and VDRs to evaluate a possible role of androgen in 1,25-(OH)2 D mediated growth inhibition. We stably introduced the AR cDNA into the human prostate cancer cell line ALVA 31, which expresses functional VDR but is relatively resistant to growth inhibition by 1,25-(OH)2 D. Neither ALVA-AR nor the control cells, ALVA-NEO, exhibited substantial growth inhibition by 1,25-(OH)2 D in the presence or absence of androgen. This observation suggests that the basis for the resistance of ALVA 31 to 1,25-(OH)2 D-mediated growth inhibition is not the lack of AR. The second model was LNCaP-104R1, an AR-expressing androgen independent prostate cancer cell line derived from androgen dependent LNCaP. 1,25-(OH)2 D inhibited the growth of LNCaP-104R1 cells in the absence of androgen and this effect was not blocked by the antiandrogen Casodex. As was observed in the parental LNCaP cells, this effect was correlated with G1 phase cell cycle accumulation and upregulation of the cyclin dependent kinase inhibitor (CKI) p27, as well as increased association of p27 with cyclin dependent kinase 2. These findings suggest that the antiproliferative effects of 1,25-(OH)2 D do not require androgen-activated AR but do involve 1,25-(OH)2 D induction of CKIs required for G1 cell cycle checkpoint control.

KW - Androgen independence

KW - Androgen receptor

KW - Cyclin dependent kinase inhibitor

KW - p21

KW - p27

KW - Vitamin D receptor

UR - http://www.scopus.com/inward/record.url?scp=0037081874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037081874&partnerID=8YFLogxK

M3 - Article

C2 - 11850123

AN - SCOPUS:0037081874

VL - 186

SP - 69

EP - 79

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - 1

ER -